公开(公告)号：US20240319210A1

公开(公告)日：2024-09-26

申请号：US18267469

申请日：2021-12-20

申请人： HUMAN METABOLOMICS INSTITUTE, INC.

发明人： Wei Jia ,  Guoxiang Xie ,  Kejun Zhou

IPC分类号： G01N33/72 ,  G01N30/02 ,  G01N30/72 ,  G01N30/88

CPC分类号： G01N33/728 ,  G01N30/7266 ,  G01N2030/027 ,  G01N2030/8822 ,  G01N2333/9108 ,  G01N2333/96419 ,  G01N2800/085

摘要： Disclosed in the present invention is an application of conjugated bilirubin as a biomarker in preparation of a diagnosis device for evaluating a risk of neonatal biliary atresia. Also disclosed in the present invention are a bilirubin content measurement method, a stable quantitative detection reagent for bilirubin, and an application of the quantitative detection reagent for bilirubin in preparation of a kit for measuring a content of the bilirubin and evaluating a risk of biliary atresia of a subject, infant hepatitis syndrome, α1 antitrypsin deficiency disease or Alagille syndrome. Also disclosed in the present invention are a kit for measuring the content of the bilirubin or evaluating the risk of neonatal biliary atresia, an application of the kit, a method for evaluating the risk of neonatal biliary atresia, and a device for predicting the risk of neonatal biliary atresia by using an expression level of the conjugated bilirubin. The present invention has the advantages of being simple and rapid, flexible in sample preparation, low in limit of detection, good in repeatability and high in sensitivity; and the sample preparation and detection method is simple and easy to implement, low in cost and suitable for popularization and use.

公开(公告)号：US20240288409A1

公开(公告)日：2024-08-29

申请号：US18571782

申请日：2022-06-20

申请人： CRESCENDO CARE S.R.L.

发明人： Francesco Chiara ,  Simona Roggero

IPC分类号： G01N30/88 ,  G01N30/02 ,  G01N30/06 ,  G01N30/72

CPC分类号： G01N30/88 ,  G01N30/06 ,  G01N30/72 ,  G01N2030/027 ,  G01N2030/062 ,  G01N2030/8818 ,  G01N2030/8822 ,  G01N2030/8827

摘要： The present invention relates to a multiresidual method for detecting and/or quantifying at least one amino acid or derivative thereof, at least one organic acid, and/or at least one modified nucleotide, in a sample of biological liquid or circulating cells, comprising the steps of: a) treating the sample with an extraction mixture at room temperature, preferably refrigerated at a temperature lower than −20° C., comprising i) a mixture of one or more organic solvents having a final polarity index between 3 and 6, ii) a strong acid in an amount sufficient for the extraction mixture to have a normality from 0.005 to 0.025 N or a weak acid with ka in the range between 3.5×10−7 and 7.0×10−3 with a final concentration in the extraction mixture from 5 to 30 mM; wherein the extraction mixture comprises: acetonitrile, dichioromethane and formic acid; or acetonitrile and hydrochloric acid; or acetone and formic acid; or methanol and formic acid; or acetonitrile and formic acid; or methanol and dimethyl sulfoxide; or acetonitrile and dimethyl sulfoxide; or acetonitrile, methanol and hydrochloric acid; or acetonitrile and methanol; b) performing a hydrophilic interaction liquid chromatography (HILIC) on the sample treated in step a); c) performing an analysis by tandem mass spectrometry on the sample obtained in step b) detecting and/or quantifying the at least one amino acid or derivative thereof, and/or the at least one organic acid, and/or the at least one modified nucleotide.

公开(公告)号：US20240255511A1

公开(公告)日：2024-08-01

申请号：US18564640

申请日：2022-05-27

申请人： HUMAN METABOLOMICS INSTITUTE, INC.

发明人： Wei Jia ,  Guoxiang Xie ,  Tianlu Chen

IPC分类号： G01N33/574 ,  G01N30/02 ,  G01N30/72 ,  G01N30/88

CPC分类号： G01N33/57438 ,  G01N30/7233 ,  G01N30/88 ,  G01N2030/027 ,  G01N2030/8822 ,  G01N2570/00

摘要： Provided in the present invention is a device for diagnosing liver cancer. The device determines the level of a biomarker in a biological sample of a subject to be a diagnostic indicator, wherein the level of the biomarker is selected from the level of one or more of taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, linolelaidic acid (C18:2n6t), maltotriose, maltose and/or lactose, α-linolenic acid, β-alanine, sebacic acid, 2-methylvaleric acid, valeric acid, isovaleric acid and hexanoic acid, and/or the ratio of secondary bile acid to primary bile acid, and/or the ratio of glycine-conjugated primary bile acid to taurine-conjugated primary bile acid, the primary bile acid being selected from cholic acid and chenodeoxycholic acid, and the secondary bile acid comprising deoxycholic acid, lithocholic acid and ursodeoxycholic acid. The diagnosis device of the present invention can be used for early diagnosis of liver cancer and liver cirrhosis, thereby buying time for patients and improving the clinical treatment effect.

公开(公告)号：US11835503B2

公开(公告)日：2023-12-05

申请号：US17234229

申请日：2021-04-19

申请人： The Cleveland Clinic Foundation

发明人： Stanley L. Hazen ,  Zeneng Wang ,  Bruce S. Levison

IPC分类号： G01N30/88 ,  C12Q1/18 ,  G01N33/68 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/7036 ,  G01N30/72 ,  C12Q1/02 ,  A61K31/496

CPC分类号： G01N30/88 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/496 ,  A61K31/7036 ,  C12Q1/025 ,  C12Q1/18 ,  G01N33/6893 ,  G01N30/7233 ,  G01N2030/8813 ,  G01N2030/8822 ,  G01N2800/04 ,  G01N2800/042 ,  G01N2800/044 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/50 ,  G01N2800/52

摘要： The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

公开(公告)号：US09970908B2

公开(公告)日：2018-05-15

申请号：US14905472

申请日：2014-07-17

申请人： Sekisui Medical Co., Ltd.

发明人： Takuya Yotani ,  Hiroaki Taira ,  Takayuki Oka ,  Hideki Muraki

IPC分类号： G01N30/34 ,  G01N30/88 ,  G01N30/16 ,  G01N33/49 ,  G01N30/02

CPC分类号： G01N30/34 ,  G01N30/16 ,  G01N30/88 ,  G01N33/491 ,  G01N2030/027 ,  G01N2030/347 ,  G01N2030/8822

摘要： A gradient liquid feed device allows reduction in size of a high performance liquid chromatography type sample analyzer. The gradient liquid feed device includes a plurality of carrier liquid reservoir tanks configured to store carrier liquids of mutually different compositions, a plurality of single plunger pumps capable of drawing and discharging the carrier liquid from the plurality of carrier liquid reservoir tanks, a mixer configured to mix the carrier liquids discharged from the plurality of liquid feed pumps and feed the mixed carrier liquid, and a pulse damper in communication with the mixer and configured to absorb pulsation that may occur during liquid feeding. The single plunger pumps have a function for variably setting a length of stroke for drawing and discharging the carrier liquid and a function for variably setting a ratio between the carrier liquid drawing time and the carrier liquid discharge time.

公开(公告)号：US09726659B2

公开(公告)日：2017-08-08

申请号：US14429977

申请日：2013-09-20

申请人： The Governing Council of the University of Toronto

发明人： Michael Wheeler ,  Kacey Prentice ,  Feihan Dai ,  Ravi Retnakaran

IPC分类号： G01N33/50 ,  A61K31/198 ,  A61K31/43 ,  C07D307/68 ,  A61K31/195 ,  A61K31/196 ,  A61K38/17 ,  G01N33/53 ,  G01N30/88

CPC分类号： G01N33/5005 ,  A61K31/195 ,  A61K31/196 ,  A61K31/198 ,  A61K31/43 ,  A61K38/177 ,  C07D307/68 ,  G01N33/5023 ,  G01N33/507 ,  G01N33/5308 ,  G01N2030/8822 ,  G01N2800/042 ,  G01N2800/50 ,  G01N2800/52 ,  Y10T436/142222

摘要： Provided are methods for identifying or monitoring a subject having, or at risk of developing, impaired glucose homeostasis. Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is shown to be a biomarker for impaired glucose homeostasis and/or conditions characterized by β-cell dysfunction. Comparing a test level of CMPF in a subject to a control level identifies subjects having, or at risk of developing, impaired glucose homeostasis. Also provided are methods of causing impaired glucose homeostasis or β-cell dysfunction and methods of screening for compounds that affect the activity of β-cells. Also provided are methods for the treatment of β-cell dysfunction by reducing the physiological levels of CMPF in a subject as well as the use of a OAT modulator for the treatment of β-cell dysfunction.

公开(公告)号：US09714886B2

公开(公告)日：2017-07-25

申请号：US14357274

申请日：2012-11-09

申请人： Sekisui Medical Co., Ltd.

发明人： Takayuki Oka ,  Takuya Yotani ,  Hideki Muraki

IPC分类号： G01N1/18 ,  G01N30/24 ,  G01N1/14 ,  G01N30/18 ,  G01N30/88 ,  G01N30/20

CPC分类号： G01N1/14 ,  G01N30/18 ,  G01N30/20 ,  G01N2030/8822

摘要： When injecting a sample into carrier-liquid channels (3A and 3B), injection shock is prevented. Septa 13 and 14 constitute the upper wall and the lower wall of a sample injection part (11) of the carrier-liquid channels (3A and 3B). A needle (27) can vertically penetrate the septum (13) on the upper wall side and also penetrate the septum (14) on the lower wall side. A needle moving unit (28) induces the needle (27) to penetrate the septum (14) on the lower wall side and induces the tip of the needle to face the inside of a sample vessel (26). A measurement pump (29) is operated for drawing and as a result a sample is drawn into the needle (27). Next, the needle (27) is extracted from the septum (14) on the lower wall side, the tip of the needle is induced to face the inside of the sample injection part (11), the measurement pump (29) is caused to discharge and as a result the sample within the needle (27) is injected.

公开(公告)号：US20160139157A1

公开(公告)日：2016-05-19

申请号：US15005801

申请日：2016-01-25

申请人： Quest Diagnostics Investments Incorporated

发明人： Nigel J. Clarke ,  Brett Holmquist ,  Gloria Kwang-Ja Lee ,  Richard E. Reitz

IPC分类号： G01N33/82

CPC分类号： G01N33/82 ,  G01N30/72 ,  G01N30/7233 ,  G01N2030/8813 ,  G01N2030/8822 ,  G01N2458/15 ,  G01N2560/00 ,  H01J49/00 ,  H01J49/004 ,  Y10T436/20 ,  Y10T436/203332 ,  Y10T436/24

摘要： Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.

公开(公告)号：US08789405B2

公开(公告)日：2014-07-29

申请号：US13284132

申请日：2011-10-28

申请人： Koji Sugiyama

发明人： Koji Sugiyama

IPC分类号： G01N30/00 ,  G01N30/88 ,  G01N30/86 ,  G01N27/447 ,  G01N33/96 ,  G01N33/72 ,  G01N30/04

CPC分类号： G01N30/88 ,  G01N27/447 ,  G01N30/86 ,  G01N30/8665 ,  G01N33/723 ,  G01N33/96 ,  G01N2030/042 ,  G01N2030/8822

摘要： A calibration method that enables calibration easily in a short time in a measurement of hemoglobin A1c by use of a separation analysis is provided. In a measurement of a hemoglobin A1c amount by use of a separation analysis, a one-point calibration using a single calibration standard is performed to obtain calibration data to be used for correcting a measured value.

摘要翻译： 提供了一种通过使用分离分析在短时间内容易地测量血红蛋白A1c的校准方法。 在通过分析分析测量血红蛋白A1c量时，使用单一校准标准进行单点校准，以获得用于校正测量值的校准数据。

公开(公告)号：US08776581B2

公开(公告)日：2014-07-15

申请号：US13806707

申请日：2011-06-23

申请人： Kwang Hee Park ,  Ik Hyun Park

发明人： Kwang Hee Park ,  Ik Hyun Park

IPC分类号： G01N13/00

CPC分类号： G01N30/00 ,  A61B5/150022 ,  A61B5/150305 ,  A61B5/150343 ,  A61B5/157 ,  A61B5/4845 ,  G01N33/4925 ,  G01N33/4972 ,  G01N2030/8822

摘要： A blood collection module includes a blood collection container that is coupled with a blood alcohol concentration detection device including an alcohol detection sensor having a detection probe that inhales an alcohol gas, and on one surface of which an inserting portion that is inserted by a detection probe of a blood alcohol concentration detection device is formed and on an outer surface of which blood inlet holes through which blood flows in are formed; and an absorption member that is provided in the blood collection container, to thus absorb examinee's blood that is introduced through the blood inlet holes, in which an alcohol gas generated from the blood absorbed by the absorption member is introduced into the alcohol detection sensor through the detection probe.

摘要翻译： 采血模块包括：血液收集容器，其与含有检测探针的酒精检测传感器的血液酒精浓度检测装置结合，所述检测传感器具有吸入醇气体的检测探针，并且其一个表面上由检测探针插入的插入部 形成血液酒精浓度检测装置，并且在其外部形成血液流过血液入口孔的外表面; 以及吸收构件，其设置在所述采集容器中，从而吸收通过所述血液入口孔引入的受检者的血液，其中由所述吸收构件吸收的血液产生的醇气体通过所述血液入口孔被引入所述酒精检测传感器， 检测探头。